Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | XIAP | P98170 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659566 | 0.87 | ALDH1A1 (0.54) | SMN1; SMN2KMT2AHPGDMAPTKDM4E | |
| SCHEMBL3656851 | 0.79 | ALDH1A1 (0.55) | SMN1; SMN2KMT2AHPGDMAPTXIAP | |
| SCHEMBL3658154 | 0.79 | MAPT (0.56) | SMN1; SMN2KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL2754021 | 0.79 | XIAP (0.64) | SMN1; SMN2KMT2AMAPTXIAPKDM4E | |
| SCHEMBL3176221 | 0.78 | XIAP (0.66) | SMN1; SMN2KMT2AMAPTXIAPKDM4E | |
| SCHEMBL3658811 | 0.77 | SMN1; SMN2 (0.38) | SMN1; SMN2KMT2AHPGDMAPTXIAP | |
| SCHEMBL1464985 | 0.77 | CNR2 (0.57) | SMN1; SMN2KMT2AHPGDMAPTXIAP | |
| SCHEMBL13015782 | 0.76 | TRPV4 (0.40) | SMN1; SMN2KMT2AHPGDMAPTKDM4E | |
| SCHEMBL3779774 | 0.75 | RAB9A (0.46) | SMN1; SMN2KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL2316516 | 0.74 | XIAP (0.57) | SMN1; SMN2KMT2AMAPTXIAPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546563-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | claimed |
| EP-2217565-B1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2013-05-22 | — | — | EP | claimed |
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-30 | — | — | US | claimed |
| US-8546563-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546563-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546563-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2217565-B1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2013-05-22 | — | — | EP | disclosed |
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331304-A1 | Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | SMN1; SMN2 4442/4885KMT2A 3644/4885HPGD 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.